Key result
Fondaparinux sodium has demonstrated superior efficacy over other anticoagulants for venous thromboembolism prophylaxis and cost savings in clinical trials and cost-effectiveness studies.
Why the study?
Does fondaparinux sodium improve efficacy and cost-effectiveness compared to other anticoagulants for venous thromboembolism prophylaxis?
Does fondaparinux sodium improve efficacy and cost-effectiveness compared to other anticoagulants for venous thromboembolism prophylaxis?
Fondaparinux sodium is an effective and cost-saving selective Factor Xa inhibitor for VTE prophylaxis that does not require coagulation monitoring and has a reduced risk of thrombocytopenia.
May support fondaparinux for VTE prophylaxis; leaves open need for updated head-to-head trials.
Fondaparinux sodium is the first in a new class of anticoagulants that selectively inhibits Factor Xa. It produces a predictable pharmacologic response, obviating the need for coagulation monitoring. Additionally, this agent does not bind to platelet Factor 4, thereby reducing the risk of thrombocytopenia. Clinical trials have repeatedly demonstrated superior efficacy over other anticoagulants as venous thromboembolism prophylaxis and several cost-effectiveness studies have demonstrated cost savings with this drug.
No takes yet. Share an insight, caveat, or question.
Wade et al. (2007) conducted a review in Deep vein thrombosis and pulmonary embolism. Fondaparinux sodium vs. Other anticoagulants was evaluated. Fondaparinux sodium has demonstrated superior efficacy over other anticoagulants for venous thromboembolism prophylaxis and cost savings in clinical trials and cost-effectiveness studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: